Aevumed

About the offering

Aevumed is a revenue-generating medical device company focused on orthopedic soft-tissue repair. The company develops FDA-cleared implants, a biologic delivery system, and an AI-powered surgical guidance platform called AiTRIUM™. Its flagship product, the PHANTOM-LP Knotless Anchor, is a 100% PEEK, self-punching, one-piece suture anchor that allows surgeons to lock, unlock, and re-tension suture after the anchor is seated in bone — a capability not available in competing products. Over 6,000 PHANTOM-LP implants have been placed in human patients. The company also has the PHANTOM-X, a 3D bioprinted scaffold designed to reinforce both superior and inferior tendon surfaces, manufactured using Aevumed's proprietary BioTendon 3D™ printing technology, which demonstrated +60% repair strength in bench testing and installs in approximately three minutes. Additional commercial products include PHANTOM, PHANTOM-3.5/4.5, PHANTOM-NANO, RAPID, SUPERCYNCH, PROTEKT, HIP LABRUM, and FASE anchors spanning shoulder, hip, foot, and ankle indications. AiTRIUM™ is a patent-pending AI surgical intelligence system that analyzes live surgical video in real time, identifies anatomical structures and injuries, provides visual overlays, delivers treatment recommendations, and supports voice interaction — all within the operating room. The system is trained on procedures from elite surgeons and continues learning from each case. Aevumed's manufacturing model is in-house, with Swiss CNC machining, robotic additive printing, and a custom 3D bioprinter that reduces prototype time from 12 weeks to approximately one week and prototype cost from $10,000 to under $100. The company reports a 75% gross margin on in-house production, trending toward 80%. Revenue grew 139% from $287K in 2022 to $684K in 2024 using one to two products and no external marketing budget, with a $5M revenue target for 2026 (contingent on the Reg CF round closing in December 2025) and a cash-flow-breakeven goal in Q4 2026. The company has filed 17 patents and processed 9 trademarks, with approximately 3 new provisional filings per year. Its target market includes the sports medicine devices sector ($6.4B–$12B, 2025–2033, 8.23% CAGR) and the broader orthopedic market ($64B). The company works with a network of 40+ elite sports-medicine surgeons who meet monthly with engineers to define R&D priorities. The leadership team includes Founder/CEO Saif Khalil, PhD (former VP Neuromodulation at Globus Medical), VP R&D Miles Curtis (former Globus Medical engineer), and SVP Sales William Warrender, Jr. (former Cardinal Health, Smith & Nephew, J&J). The board includes former CFO of Smith & Nephew Trauma Global, former Global President of Smith & Nephew Trauma & Extremities, and two former AAOS presidents. The medical advisory board features faculty from Thomas Jefferson University, Rothman Orthopaedic Institute, and HSS. The company is raising a $1.23M Regulation CF equity round via DealMaker Securities. Investment tiers range from $1,000 (standard shares) to $40,000 (with 15% bonus shares). Aevumed absorbs all platform fees, so investors receive full equity for each dollar invested. Proceeds are allocated to production scaling (35%), sales and marketing (25%), R&D pipeline (20%), regulatory and clinical studies (15%), and AI development (5%). The company's roadmap targets 10 commercial products by 2026, 18 by 2027, and a $25M+ revenue target in 2027, with an exit target above $400M.

FAQ